Zacks Research Analysts Lower Earnings Estimates for JNJ

Johnson & Johnson (NYSE:JNJ) – Analysts at Zacks Research reduced their Q2 2025 earnings estimates for shares of Johnson & Johnson in a research note issued to investors on Thursday, December 5th. Zacks Research analyst K. Shah now forecasts that the company will post earnings per share of $2.68 for the quarter, down from their previous estimate of $2.69. The consensus estimate for Johnson & Johnson’s current full-year earnings is $9.93 per share. Zacks Research also issued estimates for Johnson & Johnson’s Q3 2025 earnings at $2.66 EPS.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. The business had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the prior year, the company posted $2.66 EPS.

A number of other research analysts have also recently issued reports on the stock. Wells Fargo & Company lifted their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Royal Bank of Canada boosted their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. Wolfe Research initiated coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. Finally, Citigroup boosted their target price on shares of Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $175.67.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $149.61 on Monday. The company’s fifty day simple moving average is $157.84 and its two-hundred day simple moving average is $156.40. The firm has a market cap of $360.20 billion, a PE ratio of 21.65, a price-to-earnings-growth ratio of 2.65 and a beta of 0.51. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85.

Hedge Funds Weigh In On Johnson & Johnson

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Occidental Asset Management LLC increased its holdings in shares of Johnson & Johnson by 21.6% during the 2nd quarter. Occidental Asset Management LLC now owns 3,416 shares of the company’s stock valued at $499,000 after purchasing an additional 607 shares in the last quarter. Bangor Savings Bank grew its holdings in shares of Johnson & Johnson by 3.0% in the second quarter. Bangor Savings Bank now owns 26,933 shares of the company’s stock valued at $3,936,000 after purchasing an additional 776 shares during the period. Voisard Asset Management Group Inc. grew its holdings in shares of Johnson & Johnson by 93.2% in the second quarter. Voisard Asset Management Group Inc. now owns 1,244 shares of the company’s stock valued at $182,000 after purchasing an additional 600 shares during the period. JFS Wealth Advisors LLC boosted its stake in Johnson & Johnson by 29.6% during the second quarter. JFS Wealth Advisors LLC now owns 20,461 shares of the company’s stock worth $2,991,000 after buying an additional 4,671 shares during the period. Finally, Brendel Financial Advisors LLC purchased a new position in Johnson & Johnson during the second quarter worth about $857,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.32%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.